Clinical Trial Detail

NCT ID NCT02437318
Title Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors Novartis Pharmaceuticals
Indications

Her2-receptor negative breast cancer

Therapies

Alpelisib

Fulvestrant

Age Groups: adult

Additional content available in CKB BOOST